

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 June 2005 (09.06.2005)

PCT


(10) International Publication Number  
**WO 2005/051298 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/28**, 31/445, 31/435, C07F 9/06
- (21) International Application Number: PCT/US2004/039024
- (22) International Filing Date: 19 November 2004 (19.11.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/523,830 19 November 2003 (19.11.2003) US  
60/598,524 3 August 2004 (03.08.2004) US
- (71) Applicant (for all designated States except US):  
**METABASIS THERAPEUTICS, INC.** [US/US];  
9390 Towne Centre Drive, San Diego, CA 92121 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **ERION, Mark, D.** [US/US]; 13455 Mango Drive, Del Mar, CA 92104 (US).  
**JIANG, Hongjian** [CN/US]; 13106 Sierra Mesa Road, San Diego, CA 92129 (US). **BOYER, Serge, H.** [FR/US]; 5112 Castle Hills Drive, San Diego, CA 92109 (US).
- (74) Agents: **ESMOND, Robert, W.** et al.; **STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.**, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,


[Continued on next page]

(54) Title: NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS

Homologous Displacement Reactions



T3 Binding Assay Results



Effect of Compound 13-1-*cis* (•) and Compound 18 (o)  
on Cholesterol in Cholesterol Fed Rats

(57) Abstract: The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.



TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) **Date of publication of the international search report:**

11 August 2005

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*